ResMed Statistics
Total Valuation
ResMed has a market cap or net worth of $34.82 billion. The enterprise value is $35.23 billion.
| Market Cap | 34.82B |
| Enterprise Value | 35.23B |
Important Dates
The next estimated earnings date is Wednesday, January 22, 2025, after market close.
| Earnings Date | Jan 22, 2025 |
| Ex-Dividend Date | Nov 7, 2024 |
Share Statistics
ResMed has 146.75 million shares outstanding. The number of shares has increased by 0.02% in one year.
| Current Share Class | 146.75M |
| Shares Outstanding | 146.75M |
| Shares Change (YoY) | +0.02% |
| Shares Change (QoQ) | +0.04% |
| Owned by Insiders (%) | 0.53% |
| Owned by Institutions (%) | 74.19% |
| Float | 145.80M |
Valuation Ratios
The trailing PE ratio is 31.47 and the forward PE ratio is 24.79. ResMed's PEG ratio is 1.56.
| PE Ratio | 31.47 |
| Forward PE | 24.79 |
| PS Ratio | 7.25 |
| Forward PS | 6.64 |
| PB Ratio | 6.70 |
| P/TBV Ratio | 19.02 |
| P/FCF Ratio | 25.73 |
| P/OCF Ratio | 24.17 |
| PEG Ratio | 1.56 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 21.58, with an EV/FCF ratio of 26.03.
| EV / Earnings | 31.65 |
| EV / Sales | 7.33 |
| EV / EBITDA | 21.58 |
| EV / EBIT | 23.76 |
| EV / FCF | 26.03 |
Financial Position
The company has a current ratio of 2.92, with a Debt / Equity ratio of 0.16.
| Current Ratio | 2.92 |
| Quick Ratio | 1.44 |
| Debt / Equity | 0.16 |
| Debt / EBITDA | 0.51 |
| Debt / FCF | 0.63 |
| Interest Coverage | 40.98 |
Financial Efficiency
Return on equity (ROE) is 23.56% and return on invested capital (ROIC) is 15.72%.
| Return on Equity (ROE) | 23.56% |
| Return on Assets (ROA) | 13.27% |
| Return on Capital (ROIC) | 15.72% |
| Revenue Per Employee | $481,712 |
| Profits Per Employee | $111,511 |
| Employee Count | 9,980 |
| Asset Turnover | 0.69 |
| Inventory Turnover | 1.82 |
Taxes
In the past 12 months, ResMed has paid $263.22 million in taxes.
| Income Tax | 263.22M |
| Effective Tax Rate | 19.13% |
Stock Price Statistics
The stock price has increased by +36.69% in the last 52 weeks. The beta is 0.68, so ResMed's price volatility has been lower than the market average.
| Beta (5Y) | 0.68 |
| 52-Week Price Change | +36.69% |
| 50-Day Moving Average | 242.55 |
| 200-Day Moving Average | 219.98 |
| Relative Strength Index (RSI) | 45.38 |
| Average Volume (20 Days) | 818,650 |
Short Selling Information
The latest short interest is 7.54 million, so 5.14% of the outstanding shares have been sold short.
| Short Interest | 7.54M |
| Short Previous Month | 7.89M |
| Short % of Shares Out | 5.14% |
| Short % of Float | 5.17% |
| Short Ratio (days to cover) | 8.27 |
Income Statement
In the last 12 months, ResMed had revenue of $4.81 billion and earned $1.11 billion in profits. Earnings per share was $7.54.
| Revenue | 4.81B |
| Gross Profit | 2.80B |
| Operating Income | 1.48B |
| Pretax Income | 1.26B |
| Net Income | 1.11B |
| EBITDA | 1.63B |
| EBIT | 1.48B |
| Earnings Per Share (EPS) | $7.54 |
Balance Sheet
The company has $442.58 million in cash and $850.24 million in debt, giving a net cash position of -$407.67 million or -$2.78 per share.
| Cash & Cash Equivalents | 442.58M |
| Total Debt | 850.24M |
| Net Cash | -407.67M |
| Net Cash Per Share | -$2.78 |
| Equity (Book Value) | 5.20B |
| Book Value Per Share | 35.39 |
| Working Capital | 1.74B |
Cash Flow
In the last 12 months, operating cash flow was $1.44 billion and capital expenditures -$87.27 million, giving a free cash flow of $1.35 billion.
| Operating Cash Flow | 1.44B |
| Capital Expenditures | -87.27M |
| Free Cash Flow | 1.35B |
| FCF Per Share | $9.22 |
Margins
Gross margin is 58.33%, with operating and profit margins of 30.84% and 23.15%.
| Gross Margin | 58.33% |
| Operating Margin | 30.84% |
| Pretax Margin | 28.62% |
| Profit Margin | 23.15% |
| EBITDA Margin | 33.95% |
| EBIT Margin | 30.84% |
| FCF Margin | 28.15% |
Dividends & Yields
This stock pays an annual dividend of $2.12, which amounts to a dividend yield of 0.89%.
| Dividend Per Share | $2.12 |
| Dividend Yield | 0.89% |
| Dividend Growth (YoY) | 9.78% |
| Years of Dividend Growth | 12 |
| Payout Ratio | 28.12% |
| Buyback Yield | -0.02% |
| Shareholder Yield | 0.87% |
| Earnings Yield | 3.20% |
| FCF Yield | 3.89% |
Analyst Forecast
The average price target for ResMed is $230.11, which is -3.02% lower than the current price. The consensus rating is "Buy".
| Price Target | $230.11 |
| Price Target Difference | -3.02% |
| Analyst Consensus | Buy |
| Analyst Count | 12 |
| Revenue Growth Forecast (5Y) | 8.56% |
| EPS Growth Forecast (5Y) | 14.64% |
Stock Splits
The last stock split was on August 31, 2010. It was a forward split with a ratio of 2:1.
| Last Split Date | Aug 31, 2010 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
ResMed has an Altman Z-Score of 10.95 and a Piotroski F-Score of 6.
| Altman Z-Score | 10.95 |
| Piotroski F-Score | 6 |